116 related articles for article (PubMed ID: 2100017)
1. A novel approach to the induction of specific cytolytic T cells in vivo.
Ley V; Roth C; Langlade-Demoyen P; Larsson-Sciard EL; Kourilsky P
Res Immunol; 1990; 141(9):855-63. PubMed ID: 2100017
[TBL] [Abstract][Full Text] [Related]
2. Genetically engineered fibroblasts with antigen-presenting capability: efficient induction of an antigen-specific cytotoxic T-lymphocyte response and protection against tumor development in vivo.
Kim TS; Chung SW; Kim SH; Kang BY; Hwang SY; Lee JW
Cancer Gene Ther; 2000 Jun; 7(6):861-9. PubMed ID: 10880016
[TBL] [Abstract][Full Text] [Related]
3. Lack of correlation between rejection of tumor cells co-expressing interleukin-2 and B7.1 and vaccine efficiency.
Cayeux S; Richter G; Becker C; Beck C; Aicher A; Pezzutto A; Dörken B; Blankenstein T
Eur J Immunol; 1997 Jul; 27(7):1657-62. PubMed ID: 9247574
[TBL] [Abstract][Full Text] [Related]
4. Production of interleukin 2 and interleukin 4 by immune CD4-CD8+ and their role in the generation of antigen-specific cytotoxic T cells.
Horvat B; Loukides JA; Anandan L; Brewer E; Flood PM
Eur J Immunol; 1991 Aug; 21(8):1863-71. PubMed ID: 1907920
[TBL] [Abstract][Full Text] [Related]
5. Interleukin 2-dependent activation of tumor-specific cytotoxic T lymphocytes in vivo.
Ley V; Langlade-Demoyen P; Kourilsky P; Larsson-Sciard EL
Eur J Immunol; 1991 Mar; 21(3):851-4. PubMed ID: 2009918
[TBL] [Abstract][Full Text] [Related]
6. Tumour-specific CTL response requiring interactions of four different cell types and recognition of MHC class I and class II restricted tumour antigens.
Schirrmacher V; Schild HJ; Gückel B; von Hoegen P
Immunol Cell Biol; 1993 Aug; 71 ( Pt 4)():311-26. PubMed ID: 7901150
[TBL] [Abstract][Full Text] [Related]
7. T-cell responses induced by the parenteral injection of antigen-modified syngeneic cells. II. Mechanisms, specificity, and cellular analysis of 2,4,6-trinitrophenol (TNP)-specific cytolytic response priming by intravenous versus subcutaneous injection with TNP-modified syngeneic cells.
Miller SD; Butler LD; Cleveland RP; Moorhead JW; Claman HN; Chiller JC
Cell Immunol; 1983 Dec; 82(2):378-93. PubMed ID: 6197193
[TBL] [Abstract][Full Text] [Related]
8. Peptides derived from a wild-type murine proto-oncogene c-erbB-2/HER2/neu can induce CTL and tumor suppression in syngeneic hosts.
Nagata Y; Furugen R; Hiasa A; Ikeda H; Ohta N; Furukawa K; Nakamura H; Furukawa K; Kanematsu T; Shiku H
J Immunol; 1997 Aug; 159(3):1336-43. PubMed ID: 9233630
[TBL] [Abstract][Full Text] [Related]
9. Simian virus 40 large-T-antigen-specific rejection of mKSA tumor cells in BALB/c mice is critically dependent on both strictly tumor-associated, tumor-specific CD8(+) cytotoxic T lymphocytes and CD4(+) T helper cells.
Utermöhlen O; Schulze-Garg C; Warnecke G; Gugel R; Löhler J; Deppert W
J Virol; 2001 Nov; 75(22):10593-602. PubMed ID: 11602701
[TBL] [Abstract][Full Text] [Related]
10. Induction and characterization of minor histocompatibility antigens. Specific primary cytotoxic T lymphocyte responses in vitro.
Ando K; Nakashima I; Nagase F; Isobe K; Kawashima K; Hasegawa Y; Yoshida T; Iwamoto T; Hasegawa T; Muro Y
J Immunol; 1988 Feb; 140(3):723-9. PubMed ID: 2448374
[TBL] [Abstract][Full Text] [Related]
11. Modulation of cellular anti-tumour responses by tumour-specific T suppressor lymphocytes.
Haubeck HD; Stutenkemper R; Kölsch E
Clin Exp Immunol; 1988 Oct; 74(1):47-52. PubMed ID: 2975538
[TBL] [Abstract][Full Text] [Related]
12. Dendritic cells in antitumor immune responses. I. Defective antigen presentation in tumor-bearing hosts.
Gabrilovich DI; Ciernik IF; Carbone DP
Cell Immunol; 1996 May; 170(1):101-10. PubMed ID: 8665590
[TBL] [Abstract][Full Text] [Related]
13. Selective inhibition of antigen-induced "step one" in cytotoxic T lymphocytes by anti-Lyt-2 antibodies.
Gullberg M; Larsson EL
Eur J Immunol; 1982 Dec; 12(12):1006-11. PubMed ID: 6984390
[TBL] [Abstract][Full Text] [Related]
14. Effect of B7.1-transfected human colon cancer cells on the induction of autologous tumour-specific cytotoxic T cells.
Miyazono Y; Kamogawa Y; Ryo K; Furukawa T; Mitsuhashi M; Yamauchi K; Kameoka T; Hayashi N
J Gastroenterol Hepatol; 1999 Oct; 14(10):997-1003. PubMed ID: 10530496
[TBL] [Abstract][Full Text] [Related]
15. Development of a cancer vaccine: peptides, proteins, and DNA.
Shiku H; Wang L; Ikuta Y; Okugawa T; Schmitt M; Gu X; Akiyoshi K; Sunamoto J; Nakamura H
Cancer Chemother Pharmacol; 2000; 46 Suppl():S77-82. PubMed ID: 10950153
[TBL] [Abstract][Full Text] [Related]
16. Viral hemagglutinin augments peptide-specific cytotoxic T cell responses.
Ertel C; Millar NS; Emmerson PT; Schirrmacher V; von Hoegen P
Eur J Immunol; 1993 Oct; 23(10):2592-6. PubMed ID: 8405059
[TBL] [Abstract][Full Text] [Related]
17. Generation of IL-2-dependent cytolytic T lymphocytes (CTLs) with altered TCR responses derived from antigen-dependent CTL clones.
Gullo CA; Esser MT; Fuller CL; Lam Braciale V
J Immunol; 1999 Jun; 162(11):6466-72. PubMed ID: 10352261
[TBL] [Abstract][Full Text] [Related]
18. TCR-independent induction of low responsiveness by chemically fixed cells in alloreactive CTL clones and its prevention through cognate cell-cell interaction.
Lwin T; Nakashima I; Nagase F
Microbiol Immunol; 1995; 39(7):509-15. PubMed ID: 8569536
[TBL] [Abstract][Full Text] [Related]
19. Presentation of native TROP-2 tumor antigens to human cytotoxic T lymphocytes by engineered antigen-presenting cells.
Mangino G; Grazia Capri M; Barnaba V; Alberti S
Int J Cancer; 2002 Oct; 101(4):353-9. PubMed ID: 12209960
[TBL] [Abstract][Full Text] [Related]
20. Role of cytotoxic T lymphocytes in the prevention of lupus-like disease occurring in a murine model of graft-vs-host disease.
Via CS; Sharrow SO; Shearer GM
J Immunol; 1987 Sep; 139(6):1840-9. PubMed ID: 2957440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
